Psychiatry, the medical specialty dedicated to mental health, encompasses a vast array of disorders, treatments, and research areas. The Journal of Clinical Psychiatry provides comprehensive insights into the field, from the latest research findings to clinical best practices. Our expert editors ensure that content is evidence-based, relevant, and cutting-edge, serving as a valuable resource for psychiatrists seeking to enhance their knowledge, skills, and patient care outcomes.
PCOS symptoms extend beyond reproductive issues, with noted correlations to anxiety, depression, and suicidal attempts. This study assessed psychiatric comorbidities among hospitalized adolescent females with PCOS.
Prim Care Companion CNS Disord 2024;26(6):24m03760
Given the precipitous increase in both scientific publications and public interest in psychedelics, clinicians should learn more about how they work, what they might work for, and what their adverse effects encompass.
Prim Care Companion CNS Disord. 2024;26(5):24f03783
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”